Brief: AB Science Says Phase 2B/3 Study Evaluating Masitinib In Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Met Primary Endpoint
29/04/2021 18:09
April 29 (Reuters) - AB SCIENCE SA ABS.PA :
* PHASE 2B/3 STUDY EVALUATING MASITINIB IN IN METASTATIC
CASTRATE-RESISTANT PROSTATE CANCER (MCRPC) MET ITS PRIMARY
ENDPOINT
Source text for Eikon: ID:nGNE9G8v9R
Further company coverage: ABS.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on AB Science SA
See all newsBrief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041
Brief: AB Science Phase 1 AML Study Of AB8939 Shows 100% Partial Response Rate
Brief: AB Science Receives Notice Of Allowance For European Patent Covering Masitinib Until 2040 In Treatment Of Sickle Cell Disease